HALOZYME THERAPEUTICS, INC. (HALO) Free cash flow 2016–2025
HALOZYME THERAPEUTICS, INC. (HALO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
$644.6MFY2025 · since FY2016: -$53.5M → $644.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | $644.6M | +37.6% |
| FY2024 | $468.4M | +25.5% |
| FY2023 | $373.3M | +58.6% |
| FY2022 | $235.3M | -21.0% |
| FY2021 | $298.0M | +462.8% |
| FY2020 | $53.0M | +159.2% |
| FY2019 | -$89.5M | -65.2% |
| FY2018 | -$54.2M | -140.8% |
| FY2017 | $132.7M | +348.0% |
| FY2016 | -$53.5M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More HALO financial trends
HALO RevenueHALO Net incomeHALO Net marginHALO Gross profitHALO Gross marginHALO Operating incomeHALO Operating marginHALO Operating cash flowHALO Capital expendituresHALO Return on equityHALO Stock buybacksHALO Dividends paidHALO Total assetsHALO Total liabilitiesHALO Shareholders’ equityHALO overview →